Literature DB >> 21294655

Alterations to the blood-retinal barrier in diabetes: cytokines and reactive oxygen species.

Tiffany Frey1, David A Antonetti.   

Abstract

Diabetic retinopathy (DR) is a leading cause of blindness in Western society. Since the prevalence of diabetes continues to increase dramatically, the impact of DR will only worsen unless new therapeutic options are developed. Recent data demonstrate that oxidative stress contributes to the pathology of DR and inhibition of oxidative stress reduces retinal vascular permeability. However, direct mechanisms by which oxidative stress alters the blood-retinal barrier (BRB) and increases vascular permeability remain to be elucidated. A large body of evidence demonstrates a clear role for altered expression of cytokines and growth factors in DR, resulting in increased vascular permeability, and the molecular mechanisms for these processes are beginning to emerge. The pathology of DR is likely a result of metabolic dysregulation contributing to both oxidative stress and cytokine production. This review will examine the evidence for oxidative stress, growth factors, and other cytokines in tight junction regulation and vascular permeability in DR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21294655     DOI: 10.1089/ars.2011.3906

Source DB:  PubMed          Journal:  Antioxid Redox Signal        ISSN: 1523-0864            Impact factor:   8.401


  54 in total

1.  Inflammatory cytokine-specific alterations in retinal endothelial cell function.

Authors:  Tammy L Palenski; Christine M Sorenson; Nader Sheibani
Journal:  Microvasc Res       Date:  2013-06-24       Impact factor: 3.514

2.  Neutrophil elastase contributes to the pathological vascular permeability characteristic of diabetic retinopathy.

Authors:  Haitao Liu; Emma M Lessieur; Aicha Saadane; Sarah I Lindstrom; Patricia R Taylor; Timothy S Kern
Journal:  Diabetologia       Date:  2019-10-14       Impact factor: 10.122

Review 3.  The inner blood-retinal barrier: Cellular basis and development.

Authors:  Mónica Díaz-Coránguez; Carla Ramos; David A Antonetti
Journal:  Vision Res       Date:  2017-06-27       Impact factor: 1.886

Review 4.  Targeting inflammation in diabetes: Newer therapeutic options.

Authors:  Neeraj Kumar Agrawal; Saket Kant
Journal:  World J Diabetes       Date:  2014-10-15

Review 5.  Diabetic retinopathy: Breaking the barrier.

Authors:  Randa S Eshaq; Alaa M Z Aldalati; J Steven Alexander; Norman R Harris
Journal:  Pathophysiology       Date:  2017-07-12

6.  The unfolded protein response to endoplasmic reticulum stress in cultured astrocytes and rat brain during experimental diabetes.

Authors:  Katrine R Lind; Kelly K Ball; Nancy F Cruz; Gerald A Dienel
Journal:  Neurochem Int       Date:  2013-02-11       Impact factor: 3.921

Review 7.  Diabetic retinopathy: current understanding, mechanisms, and treatment strategies.

Authors:  Elia J Duh; Jennifer K Sun; Alan W Stitt
Journal:  JCI Insight       Date:  2017-07-20

8.  Aralia elata inhibits neurodegeneration by downregulating O-GlcNAcylation of NF-κB in diabetic mice.

Authors:  Seong-Jae Kim; Min-Jun Kim; Mee-Young Choi; Yoon-Sook Kim; Ji-Myong Yoo; Eun-Kyung Hong; Sunmi Ju; Wan-Sung Choi
Journal:  Int J Ophthalmol       Date:  2017-08-18       Impact factor: 1.779

Review 9.  The role of O-GlcNAc signaling in the pathogenesis of diabetic retinopathy.

Authors:  Richard D Semba; Hu Huang; Gerard A Lutty; Jennifer E Van Eyk; Gerald W Hart
Journal:  Proteomics Clin Appl       Date:  2014-02-19       Impact factor: 3.494

10.  Retinal angiogenesis in the Ins2(Akita) mouse model of diabetic retinopathy.

Authors:  Zongchao Han; Junjing Guo; Shannon M Conley; Muna I Naash
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-01-17       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.